BIO-TECHNE Corp (TECH) : Mairs Power Inc scooped up 40,690 additional shares in BIO-TECHNE Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,351,264 shares of BIO-TECHNE Corp which is valued at $149,841,665.BIO-TECHNE Corp makes up approximately 1.98% of Mairs Power Inc’s portfolio.
Other Hedge Funds, Including , Balyasny Asset Management boosted its stake in TECH in the latest quarter, The investment management firm added 2,196 additional shares and now holds a total of 4,892 shares of BIO-TECHNE Corp which is valued at $542,474.Atlanta Capital Management Co L L C reduced its stake in TECH by selling 5,246 shares or 0.42% in the most recent quarter. The Hedge Fund company now holds 1,243,952 shares of TECH which is valued at $137,941,837. BIO-TECHNE Corp makes up approx 0.90% of Atlanta Capital Management Co L L C’s portfolio.Cable Hill Partners boosted its stake in TECH in the latest quarter, The investment management firm added 10 additional shares and now holds a total of 39 shares of BIO-TECHNE Corp which is valued at $4,392. Lasalle Street Capital Management added TECH to its portfolio by purchasing 2,111 company shares during the most recent quarter which is valued at $235,334. BIO-TECHNE Corp makes up approx 0.22% of Lasalle Street Capital Management’s portfolio.
BIO-TECHNE Corp opened for trading at $105.16 and hit $107.52 on the upside on Thursday, eventually ending the session at $106.53, with a gain of 1.12% or 1.18 points. The heightened volatility saw the trading volume jump to 2,29,390 shares. Company has a market cap of $3,973 M.
On the company’s financial health, BIO-TECHNE Corp reported $0.92 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Aug 17, 2016. Analyst had a consensus of $0.93. The company had revenue of $134.80 million for the quarter, compared to analysts expectations of $128.91 million. The company’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.